BiotechTube
Predica Diagnostics

Predica Diagnostics

Amsterdam, Netherlands· Est.
predica-diagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Predica Diagnostics is an early-stage diagnostics company leveraging its proprietary ciRNAseq technology to develop non-invasive tests for cancer. Its lead program, CervicaDx, aims to improve cervical cancer screening by identifying high-risk lesions with higher specificity, thereby reducing unnecessary procedures. The company has established key partnerships, secured intellectual property, and is actively engaged in product development and validation. Predica operates as a private, pre-revenue entity with a small, specialized team driving its research and business strategy.

OncologyWomen's Health

Technology Platform

Proprietary ciRNAseq (circular RNA sequencing) technology for non-invasive biomarker analysis to enable precise diagnosis, prognosis, and treatment guidance in cancer.

Opportunities

The global need for higher-specificity cervical cancer screening presents a large addressable market to reduce overtreatment and healthcare costs.
The proprietary ciRNAseq platform also has potential for expansion into other cancer types and complex disease monitoring, offering long-term growth avenues.

Risk Factors

Key risks include the failure of the lead CervicaDx test to demonstrate superior clinical utility in large-scale trials, challenges in displacing established screening protocols and gaining market adoption, and intense competition from other molecular diagnostic developers.
The company also faces execution and funding risks inherent to its early-stage, pre-revenue status.

Competitive Landscape

Predica operates in the competitive molecular diagnostics for cervical cancer space, competing against companies developing HPV mRNA tests (e.g., Roche, BD, Hologic) and methylation-based assays. Its differentiation hinges on the performance claims of its ciRNAseq technology. It also competes broadly within the NGS-based IVD market, where scalability and cost-effectiveness are critical.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →